BACKGROUND: Circulating acyl-carnitines (acyl-CNTs) are associated with insulin resistance (IR) and type 2 diabetes (T2D) in both rodents and humans. However, the mechanisms whereby circulating acyl-CNTs are increased in these conditions and their role in whole-body metabolism remains unknown. The purpose of this study was to determine if, in humans, blood cells contribute in production of circulating acyl-CNTs and associate with whole-body fat metabolism. METHODS AND RESULTS: Eight non-diabetic healthy women (age: 47 ± 19 y; BMI: 26 ± 1 kg·m-2) underwent stable isotope tracer infusion and hyperinsulinemic-euglycemic clamp study to determine in vivo whole-body fatty acid flux and insulin sensitivity. Blood samples collected at baseline (0 min) and after 3 h of clamp were used to determine the synthesis rate of palmitoyl-carnitine (palmitoyl-CNT) in vitro. The fractional synthesis rate of palmitoyl-CNT was significantly higher during hyperinsulinemia (0.788 ± 0.084 vs. 0.318 ± 0.012%·hr-1, p = 0.001); however, the absolute synthesis rate (ASR) did not differ between the periods (p = 0.809) due to ∼30% decrease in blood palmitoyl-CNT concentration (p = 0.189) during hyperinsulinemia. The ASR of palmitoyl-CNT significantly correlated with the concentration of acyl-CNTs in basal (r = 0.992, p < 0.001) and insulin (r = 0.919, p = 0.001) periods; and the basal ASR significantly correlated with plasma palmitate oxidation (r = 0.764, p = 0.027). CONCLUSION: In women, blood cells contribute to plasma acyl-CNT levels and the acyl-CNT production is linked to plasma palmitate oxidation, a marker of whole-body fat metabolism. Future studies are needed to confirm the role of blood cells in acyl-CNT and lipid metabolism under different physiological (i.e., in response to meal) and pathological (i.e., hyperlipidemia, IR and T2D) conditions.
BACKGROUND: Circulating acyl-carnitines (acyl-CNTs) are associated with insulin resistance (IR) and type 2 diabetes (T2D) in both rodents and humans. However, the mechanisms whereby circulating acyl-CNTs are increased in these conditions and their role in whole-body metabolism remains unknown. The purpose of this study was to determine if, in humans, blood cells contribute in production of circulating acyl-CNTs and associate with whole-body fat metabolism. METHODS AND RESULTS: Eight non-diabetic healthy women (age: 47 ± 19 y; BMI: 26 ± 1 kg·m-2) underwent stable isotope tracer infusion and hyperinsulinemic-euglycemic clamp study to determine in vivo whole-body fatty acid flux and insulin sensitivity. Blood samples collected at baseline (0 min) and after 3 h of clamp were used to determine the synthesis rate of palmitoyl-carnitine (palmitoyl-CNT) in vitro. The fractional synthesis rate of palmitoyl-CNT was significantly higher during hyperinsulinemia (0.788 ± 0.084 vs. 0.318 ± 0.012%·hr-1, p = 0.001); however, the absolute synthesis rate (ASR) did not differ between the periods (p = 0.809) due to ∼30% decrease in blood palmitoyl-CNT concentration (p = 0.189) during hyperinsulinemia. The ASR of palmitoyl-CNT significantly correlated with the concentration of acyl-CNTs in basal (r = 0.992, p < 0.001) and insulin (r = 0.919, p = 0.001) periods; and the basal ASR significantly correlated with plasma palmitate oxidation (r = 0.764, p = 0.027). CONCLUSION: In women, blood cells contribute to plasma acyl-CNT levels and the acyl-CNT production is linked to plasma palmitate oxidation, a marker of whole-body fat metabolism. Future studies are needed to confirm the role of blood cells in acyl-CNT and lipid metabolism under different physiological (i.e., in response to meal) and pathological (i.e., hyperlipidemia, IR and T2D) conditions.
Authors: Timothy R Koves; John R Ussher; Robert C Noland; Dorothy Slentz; Merrie Mosedale; Olga Ilkayeva; James Bain; Robert Stevens; Jason R B Dyck; Christopher B Newgard; Gary D Lopaschuk; Deborah M Muoio Journal: Cell Metab Date: 2008-01 Impact factor: 27.287
Authors: Xiao-Jun Zhang; Noe A Rodriguez; Lijian Wang; Demidmaa Tuvdendorj; Zhanpin Wu; Alai Tan; David N Herndon; Robert R Wolfe Journal: J Lipid Res Date: 2011-09-20 Impact factor: 5.922
Authors: Demidmaa Tuvdendorj; Xiao-jun Zhang; David L Chinkes; Lijian Wang; Zhanpin Wu; Noe A Rodriguez; David N Herndon; Robert R Wolfe Journal: Metabolism Date: 2015-01-08 Impact factor: 8.694
Authors: B A Ellis; A Poynten; A J Lowy; S M Furler; D J Chisholm; E W Kraegen; G J Cooney Journal: Am J Physiol Endocrinol Metab Date: 2000-09 Impact factor: 4.310
Authors: Jill A Kanaley; Samyah Shadid; Michael T Sheehan; ZengKui Guo; Michael D Jensen Journal: Am J Physiol Endocrinol Metab Date: 2013-07-02 Impact factor: 4.310
Authors: Sean H Adams; Charles L Hoppel; Kerry H Lok; Ling Zhao; Scott W Wong; Paul E Minkler; Daniel H Hwang; John W Newman; W Timothy Garvey Journal: J Nutr Date: 2009-04-15 Impact factor: 4.798
Authors: Magnus Wolf; Shili Chen; Xinjie Zhao; Mika Scheler; Martin Irmler; Harald Staiger; Johannes Beckers; Martin Hrabé de Angelis; Andreas Fritsche; Hans-Ulrich Häring; Erwin D Schleicher; Guowang Xu; Rainer Lehmann; Cora Weigert Journal: J Clin Endocrinol Metab Date: 2013-04-30 Impact factor: 5.958
Authors: Jake E Lowry; Batbayar Tumurbaatar; Claudia D'Agostino; Erika Main; Traver J Wright; Edgar L Dillon; Tais B Saito; Craig Porter; Clark R Andersen; Douglas L Brining; Janice J Endsley; Melinda Sheffield-Moore; Elena Volpi; Rong Fang; Nicola Abate; Demidmaa R Tuvdendorj Journal: Br J Nutr Date: 2019-12-28 Impact factor: 3.718